CAR-T Enhancement by Combined TCR Knockdown and the RIAD Peptide Addition

Chimeric antigen receptor (CAR) is a recombinant fusion protein comprised of an antibody-derived targeting fragment and signaling domains capable to activate T cells. Ongoing clinical trials have demonstrated the remarkable ability of CAR-modified T cells to eliminate B cell malignancies.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Alexey Petukhov, Vitalia Markova, Pavel Gershovich, Alexey Titov, Evgeny Smirnov, Ekaterina Zaikova, Dmitry Motorin, Elena Petersen, Alexandr Karabelskii, Roman Ivanov, Andrey Zaritskey Source Type: research